The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Allan D. Sniderman

Mike Rosenbloom Laboratory for Cardiovascular Research

McGill University

Montreal

Quebec

Canada

[email]@*.mcgill.ca

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University, Montreal, Quebec, Canada. 2000 - 2007
  • Division of Cardiology, McGill University Health Centre, Montreal, Quebec, Canada. 2005
  • McGill University, Montreal, Que. 2000
  • Royal Victoria Hospital, Montreal, Canada. 2000

References

  1. Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go. Sniderman, A.D. Curr. Opin. Endocrinol. Diabetes. Obes (2007) [Pubmed]
  2. Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. Sniderman, A.D., Bhopal, R., Prabhakaran, D., Sarrafzadegan, N., Tchernof, A. Int. J. Epidemiol (2007) [Pubmed]
  3. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease. Sniderman, A.D., Jungner, I., Junger, I., Holme, I., Aastveit, A., Walldius, G. J. Intern. Med. (2006) [Pubmed]
  4. If apoB is so good, why isn't everybody measuring it? One reason why we need The Netherlands Journal of Medicine!. Sniderman, A.D., Rosenbloom, M. Neth. J. Med (2005) [Pubmed]
  5. Insights from apoB: from better diagnosis & therapy to the Medusa Hypothesis. Sniderman, A., Williams, K., Haffner, S., Sattar, N. Atheroscler. Suppl (2004) [Pubmed]
  6. Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. Sniderman, A.D. Curr. Opin. Lipidol. (2004) [Pubmed]
  7. Is there value in liver function test and creatine phosphokinase monitoring with statin use?. Sniderman, A.D. Am. J. Cardiol. (2004) [Pubmed]
  8. Effects on apoB-100 secretion and bile acid synthesis by redirecting cholesterol efflux from HepG2 cells. Sniderman, A.D., Zhang, Z., Genest, J., Cianflone, K. J. Lipid Res. (2003) [Pubmed]
  9. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Sniderman, A.D., Furberg, C.D., Keech, A., Roeters van Lennep, J.E., Frohlich, J., Jungner, I., Walldius, G. Lancet (2003) [Pubmed]
  10. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Sniderman, A.D., Blank, D., Zakarian, R., Bergeron, J., Frohlich, J. Clin. Biochem. (2003) [Pubmed]
  11. Hypertriglyceridemic hyperapoB in type 2 diabetes. Sniderman, A.D., Lamarche, B., Tilley, J., Seccombe, D., Frohlich, J. Diabetes. Care (2002) [Pubmed]
  12. Lipoprotein(a) and atherogenesis: a puzzle inside a riddle within an enigma. Sniderman, A.D. Clin. Invest. Med (2002) [Pubmed]
  13. How, when, and why to use apolipoprotein B in clinical practice. Sniderman, A.D. Am. J. Cardiol. (2002) [Pubmed]
  14. Apolipoprotein B versus lipoprotein lipids: vital lessons from the AFCAPS/TexCAPS trial. Sniderman, A.D., Bergeron, J., Frohlich, J. CMAJ (2001) [Pubmed]
  15. High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol. Sniderman, A.D., Dagenais, G.R., Cantin, B., Després, J.P., Lamarche, B. Am. J. Cardiol. (2001) [Pubmed]
  16. How should FCHL be defined and how should we think about its metabolic bases?. Sniderman, A.D., Ribalta, J., Castro Cabezas, M. Nutr. Metab. Cardiovasc. Dis (2001) [Pubmed]
  17. The need for greater involvement of regulatory agencies in assessing adverse drug reactions. Sniderman, A.D. CMAJ (2000) [Pubmed]
  18. Of mice and men (and women) and the acylation-stimulating protein pathway. Sniderman, A.D., Maslowska, M., Cianflone, K. Curr. Opin. Lipidol. (2000) [Pubmed]
  19. Postprandial hypertriglyceridemia(s): time to enlarge our pathophysiologic perspective. Sniderman, A.D. Eur. J. Clin. Invest. (2000) [Pubmed]
 
WikiGenes - Universities